trending Market Intelligence /marketintelligence/en/news-insights/trending/tnyy7mnrphrosor5iagsbg2 content esgSubNav
In This List

Report: MiMedx facing US DOJ probe over business practices

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Report: MiMedx facing US DOJ probe over business practices

The U.S. Justice Department is investigating whether biotech firm MiMedx Group Inc. overcharged the government for its tissue repair products, Bloomberg News reported, citing anonymous sources.

The regulator is also looking into the Georgia-based company's distribution practices, including whether it improperly recorded sales of products that were not ordered, a practice known as channel stuffing.

MiMedx said it is not aware of any such investigations, the news outlet reported citing a company statement.

MiMedx's stock price was down 10.73% to $6.99 as of 12:44 p.m. ET on Feb. 26.